Items tagged with Drug-resistant TB
MSF supports TB survivors’ court case for Indian government to override patents on lifesaving TB drugs (post)
New Delhi/Geneva, 20 April 2021 – Next week the Indian government is expected to decide whether it is willing to override patents on two critical tuberculosis (TB) drugs following a court petition filed at the Mumbai High Court by two survivors of TB and activists. If the government is willing to issue the ‘compulsory licenses,’ it would increase access to the newer TB drugs bedaquiline and delamanid for people with multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB in India. The international medical humanitarian organisation Médecins Sans Frontières/Doctors Without Borders (MSF) supports the court petition and urges the Indian government to take this critical step that would allow price-lowering competition among generic manufacturers for drug-resistant (DR) TB medicines in India.
Guidance for the surveillance of drug resistance in TB (post)
The World Health Organization (WHO) released the sixth edition of the Guidance for the surveillance of drug resistance in tuberculosis aiming to assist national TB programs in developing the strongest possible mechanisms of surveillance for drug resistance in TB, building on more than 25 years of global experience.
Tailor-made therapy of multidrug-resistant TB (post)
The successful treatment of multidrug-resistant tuberculosis requires clarification in advance as to which antibiotics the pathogens are resistant to. Classic testing in the laboratory is very time-consuming and delays the start of therapy. Researchers from the Research Center Borstel, the Leibniz Lung Center, and the German Center for Infection Research (DZIF) have now prepared a catalogue of all mutations in the genome of tuberculosis bacteria and on the basis of a genome sequencing can quickly and cheaply predict which medicines are most effective for tuberculosis treatment. The results of this work were published in the professional journal Clinical Infectious Diseases.
RESIST-TB April 2021 newsletter (post)
RESIST-TB released its April 2021 newsletter with the latest research publications on drug-resistant TB.
Bedaquiline plus delamanid may be viable option for multidrug-resistant TB (post)
Patients with multidrug-resistant or rifampicin-resistant tuberculosis (TB) and a normal baseline QTc interval may benefit from bedaquiline plus delamanid combination therapy, according to the findings of a study published in The Lancet Infectious Diseases.
Low-dose amikacin as alternative treatment for multidrug-resistant TB (post)
Low-dose amikacin with appropriate dose adjustment based on adequate monitoring demonstrated limited toxicity with positive outcomes as a treatment option for multidrug-resistant tuberculosis (MDR-TB), according to the findings of a retrospective cohort study published in BMC Infectious Diseases.
RESIST-TB May 2021 newsletter (post)
RESIST-TB released its May 2021 newsletter with the latest research publications on drug-resistant TB.
Community engagement lessons learned: A community perspective within STREAM clinical trial (post)
STREAM is the first large-scale, multi-country clinical trial to investigate shortened regimens for multidrug-resistant TB (MDR-TB), and the first phase III trial to test the efficacy and safety of bedaquiline, a new drug with a novel mechanism of action, within a shortened treatment regimen.
WHO releases the first catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance (post)
25 June 2021, Geneva | The first WHO Catalogue of mutations in the Mycobacterium tuberculosis genome complex and their association with drug resistance has been released today. The catalogue fills a critical need, providing a standard reference for the interpretation of mutations conferring resistance to all first-line and a variety of second-line drugs. The report summarises the analysis of over 38,000 isolates with matched data on whole genome sequencing and phenotypic drug susceptibility testing from over 40 countries on 13 anti-TB medicines. The catalogue lists over 17,000 mutations, their frequency and association with or not with resistance.
WHO: Public call for individual patient data on treatment of drug-resistant TB (post)
The World Health Organization (WHO) is initiating the development of new guidelines on the treatment of drug-resistant TB to support countries in the programmatic management of drug-resistant TB.
Page 69 of 117 · Total posts: 0
←First 68 69 70 Last→